VERA (Vera Therapeutics) Forward PE Ratio : 0.00 (As of Dec. 13, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Vera Therapeutics Forward PE Ratio?

Vera Therapeutics's Forward PE Ratio for today is 0.00.

Vera Therapeutics's PE Ratio without NRI for today is 0.00.

Vera Therapeutics's PE Ratio (TTM) for today is 0.00.

Vera Therapeutics Forward PE Ratio Historical Data

The historical data trend for Vera Therapeutics's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vera Therapeutics Forward PE Ratio Chart

Vera Therapeutics Annual Data

Trend

Forward PE Ratio

Vera Therapeutics Quarterly Data

Forward PE Ratio

Competitive Comparison of Vera Therapeutics's Forward PE Ratio

For the Biotechnology subindustry, Vera Therapeutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vera Therapeutics's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vera Therapeutics's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Vera Therapeutics's Forward PE Ratio falls into.

Vera Therapeutics Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Vera Therapeutics (NAS:VERA) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Vera Therapeutics Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Vera Therapeutics's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Vera Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vera Therapeutics Inc (NAS:VERA) » Definitions » Forward PE Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

8000 Marina Boulevard, Suite 120, Brisbane, CA, USA, 94005

Website

https://www.veratx.com

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Executives

Marshall Fordyce	director, officer: President and CEO	C/O VERA THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 120, BRISBANE CA 94005
Beth C Seidenberg	director
Joseph R Young	officer: SVP, Finance, Chief Acct Offcr	C/O VERA THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 120, BRISBANE CA 94005
Sean Grant	officer: Chief Financial Officer	C/O VERA THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 120, BRISBANE CA 94005
Maha Katabi	director, 10 percent owner	SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Commodore Capital Lp	10 percent owner	444 MADISON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Celia Lin	officer: Chief Medical Officer	C/O VERA THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 120, BRISBANE CA 94005
Joanne Curley	officer: Chief Development Officer	C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Patrick G Enright	director, 10 percent owner	CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Longitude Prime Fund, L.p.	10 percent owner	2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Longitude Prime Partners, Llc	10 percent owner	2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Longitude Capital Partners Iv, Llc	10 percent owner	2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Sofinnova Venture Partners X, L.p.	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Sofinnova Management X-a, L.l.c.	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Llp Abingworth	10 percent owner	38 JERMYN STREET, LONDON X0 SW1Y 6DN